This episode of the VJHemOnc podcast explores the current and future role of BTK inhibition across several non-Hodgkin lymphoma (NHL) subtypes.

First, Charalampia Kyriakou, MD, PhD, University College London Hospitals NHS Trust (UCLH), London, UK, Steven Treon, MD, PhD, FRCP, Dana-Farber Cancer Institute, Boston, MA, and Anna Maria Frustaci, MD, Niguarda Hospital, Milan, Italy, provide insight into the established role of BTK inhibitors (BTKis) in Waldenström’s macroglobulinemia (WM). Following this, Krish Patel, MD, Sarah Cannon Research Institute, Nashville, TN, Manali Kamdar, MD, University of Colorado Cancer Center, Denver, CO, and Tycel Phillips, MD, FASCO, City of Hope, Duarte, CA, discuss the shift of BTKis to the frontline setting in mantle cell lymphoma (MCL), and outline therapeutic approaches being evaluated for patients who relapse on these agents. Next, Alexey Danilov, MD, PhD, City of Hope, Duarte, CA, highlights why BTKis have not had the same impact in follicular lymphoma (FL) as in other B-cell malignancies, and comments on their current role in this disease, before Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the value of newer-generation BTK inhibitors in relapsed/refractory (R/R) indolent B-cell lymphoma. To conclude, Dr Kamdar shares insight into the potential role of BTKis in diffuse large B-cell lymphoma (DLBCL).